Author

E. L. Rivers

AstraZeneca (United Kingdom)ORCID 0000-0001-5968-8573Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Research Focus:metabolism & bioenergetics· 1 Organism:mouse· 1

Frequent Co-Authors

Abhishek SrivastavaiD· 1 shared David M. SmithiD· 1 shared James D. RobinsoniD· 1 shared James L. TrevaskisiD· 1 shared Jon A. ReadiD· 1 shared JOSEFINE L. HANSENiD· 1 shared KARLY M. MATHERiD· 1 shared Marianne SchimpliD· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

Abhishek SrivastavaORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Pharmacology & ToxicologybioRxivPreprintMay 30, 2024

Direct β1/β2 AMPK activation reduces liver steatosis but not fibrosis in a mouse model of non-alcoholic steatohepatitis

KARLY M. MATHER, Michelle L. Boland, E. L. Rivers…·David M. Smith

This study evaluates BI9774, an AMPK activator, in a mouse model of NASH, finding it reduces liver steatosis but not fibrosis and causes cardiac side effects.

5 citations

mousebulk RNA-seq

𝕏 PostBluesky